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Abstract—The effect of vitamin B2 (riboflavin) on oxidant-mediated acute lung in-
jury has been examined in three different rat models. Pulmonary injury was in-
duced by intravenous injection of cobra venom factor (CVF), by the intrapulmonary
deposition of IgG immune complexes, or by hind limb ischemia-reperfusion. In each
of the three models, injury was characterized by increases in vascular permeability
(leakage of 125I-labeled bovine serum albumin), alveolar hemorrhage (extravasation
of 51Cr-labeled rat erythrocytes), and neutrophil accumulation (myeloperoxidase
activity). Intraperitoneal administration of riboflavin at a dose of 6 ^moles/kg body
weight reduced vascular leakage by 56% in the CVF model, by 31% in the immune
complex model, and by 53% in the lung injury model following ischemia-reperfusion
of the hind limbs. Similar treatment reduced hemorrhage by 76%, 51%, and 70% in
the three models of lung injury. In the CVF model, riboflavin was also shown to
decrease products of lipid peroxidation (conjugated dienes) in lungs (by 45%) and
in plasma (by 74%). Neutrophil accumulation in the lungs was not influenced by
riboflavin administration in any of the three models. The studies demonstrate that
riboflavin can mount a significant protection against oxidant-mediated inflammatory
organ injury.
INTRODUCTION
Oxygen-derived free radicals have been shown to participate in many forms of
acute inflammatory reactions (1, 2), and have also been related to the devel-
opment of complement- and neutrophil-dependent acute lung injury in various
experimental rat models (3-6). For example, catalase or superoxide dismutase
significantly attenuated lung microvascular injury in rats that had developed
acute lung injury as a consequence of systemic complement activation follow-
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ing the injection of cobra venom factor (3). Immune complex-induced alveoli-
tis in the rat has also been shown to be oxygen radical-dependent (4). More
recently, ischemia-reperfusion injury in rat hind limbs has been shown to cause
remote pulmonary injury as demonstrated by the development of lung microvas-
cular damage and alveolar hemorrhage (5). In this model, administration of var-
ious antioxidants resulted in a significant reduction in the microvascular injury
observed in lungs and limb muscle, suggesting that oxygen radicals are involved
as well.
Several natural antioxidants and detoxifying redox enzymes exist in bio-
logical systems, including glutathione, ascorbic acid, vitamin E, catalase and
superoxide dismutase (7, 8). A derivative of vitamin B2 has been shown to pro-
tect mitochondria from adriamycin-induced oxidative stress (9) and vitamin B2,
riboflavin, has been proposed to function as an antioxidant in protecting against
reperfusion injury (10). Riboflavin easily passes into cells, where an intracellular
flavin reductase can catalyze its reduction (rxn 1). The product of this cataly-
sis, dihydroriboflavin, rapidly reduces the higher oxidation states of a number
of hemeproteins (rxn 2) and,
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Dihydroriboflavin + Hemeprotein-H2O2 —> Riboflavin + Hemeprotein + 2H2O
in the case of the reduction of the myoglobin-H2O2 complex, protects the protein
against oxidative damage (11-13). Since the higher oxidation states of iron (gen-
erated in rxn 3 by reaction with peroxides) may contribute appreciably to the
oxidative damage of cells under pathological conditions, the findings suggested
that rxns 1 and 2 might constitute a means by which cells can be protected from
such damage. Preliminary studies have indeed provided evidence that riboflavin
does protect cells and organs from oxidative damage (10, 13-15).
In the present study, we examined the ability of riboflavin to protect rats
against oxygen radical-mediated lung injury whether induced by the intravenous
injection of cobravenom factor (CVF), the intrapulmonary deposition of IgG im-
mune complexes, or following bilateral hind limb ischemia-reperfusion. We pro-
vide evidence that riboflavin, in all three types of rat pulmonary injury, reduces
both lung microvascular leakage and alveolar hemorrhage. This, and our obser-
vation that riboflavin treatment also attenuates the appearance of lipid peroxi-
dation products in lungs and plasma of injured animals, suggests that riboflavin
may play a role as antioxidant in inflammatory reactions.
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METHODS
Animal Models. For all experimental models, specific pathogen-free male Long-Evans rats
(300-350 g) (Charles River Laboratories, Portage, Michigan) were used. Rats were anesthetized
initially by an intraperitoneal injection of ketamine hydrochloride (150 mg/kg body weight (BW);
Parke Davis, Morris Plains, New Jersey). Rats subjected to ischemia-reperfusion injury received an
additional injection of butorphanol (2 mg/kg BW; Bristol-Myers, Evansville, Indiana). Subsequent
doses of ketamine (50 mg/kg) and butorphanol (2 mg/kg per 4 h) were given to sustain anesthesia
throughout the experiments.
All experiments were performed according to the standards in "The Guide for the Care and
Use of Laboratory Animals," DHEW Publication No. (NIH) 78/23, and were supervised by the
Unit for Laboratory Animal Care of the University of Michigan Medical School. Unless otherwise
indicated, all reagents were purchased from Sigma Chemical Corp. (St. Louis, Missouri).
GVF-Induced Lung Injury. Anesthetized rats were injected intravenously with 20 units of
cobra venom factor (CVF) per kg body weight together with an aliquot of 125I-labeled bovine serum
albumin (125I-BSA) and 51 Cr-labeled rat erythrocytes (51 Cr-RBC) (see below). After 30 min, animals
were exsanguinated via the posterior vena cava. The lungs were then removed and the pulmonary
vasculature was flushed with 10 ml phosphate-buffered saline (PBS). The amount of radioactivity
remaining within the lung tissue was assessed with a gamma scintillation counter. Lung damage was
defined by increases in lung vascular leakage (125I-BSA) and lung hemorrhage (51Cr-RBC). Further
details are given below.
IgG Immune Complex Alveolitis. Anesthetized rats simultaneously received 2.5 mg anti-BSA
(rabbit polyclonal IgG, Organon Teknika, West Chester, Pennsylvania) in 0.3 ml saline by intratra-
cheal administration and 10 mg BSA in 0.5 ml saline by intravenous injection. Animals were killed
after 4 h, the lungs were removed and the vasculature was flushed with 10 ml of PBS. Vascular
permeability and hemorrhage were assessed as mentioned below.
Ischemia-Reperfusion Injury. Anesthetized rats received a tourniquet which was placed on
both hind limbs proximal to the trochanter major. After 4 h of ischemia, the tourniquet was released
and reperfusion proceeded for up to 4 h. During ischemia, no blood flow was detectable using a laser
Doppler velocimeter (LD 6000 Med Pacific, Seattle, Washington), whereas normal blood flow was
detectable within the first 10 minutes of reperfusion. Animals were killed after 4 h of reperfusion
by an overdose of ketamine. Again, the lungs were removed for injury determinations, and blood
was drawn from the posterior vena cava. Furthermore, muscle specimens (5 g) from each hind limb
were taken.
Vascular Permeability and Hemorrhage. For assessment of lung and muscle vascular perme-
ability, 0.5 ml of sterile 0.9% saline containing 0.5 /*Ci 125Iodine-labeled bovine serum albumin
(125I-BSA) was injected intravenously at the time of tourniquet release. The 125I-BSA was prepared
by incubating 100 jtCi 125I in 10 ml of 2.5% BSA-phosphate-buffered saline solution (PBS) for 30
min at 21°C. Hemorrhage was measured by intravenous injection of 0.5 ml51 Cr-labeled rat erythro-
cytes (RBC) at the time of tourniquet release. To prepare 51 Cr-labeled rat RBC, 9 ml of rat blood
were diluted with 40 ml saline containing heparin (10 U/ml). Then 100 fiCi 5lCr were added, and
the RBC were incubated for 1 h at 37°C with continuous shaking. After centrifugation at 200 x g
(at 4°C) for 6 min, the red cells were washed three times in PBS and the radioactivity determined
(approx. 80,000 cpm/0.5 ml).
In the experiments, 51 Cr-labeled RBC were injected intravenously together with the 125I-BSA.
At the end of each experiment, 1 ml of venous blood was drawn from the posterior vena cava after
laparotomy. Lungs were then removed and the vasculature flushed with 10 ml of 0.9% saline via
the pulmonary artery. From each hind limb the crural muscle group (5.0 g) was harvested after
dissection of the skin. Tissue and blood samples were counted using a gamma scintillation counter
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(Gamma Trac 1191, TM Analytic, ELS Grove Village, Illinois). Lung or muscle vascular leakage and
hemorrhage values were expressed as the tissue to blood ratio of 125I-BSA and 51Cr, respectively.
Riboflavin (Vitamin B2). Riboflavin was prepared as a saturated solution (approx. 300 /iM)
in 0.9% saline (at 37°C) containing 50 mM glucose. The glucose served as a metabolite to allow
intracellular reduction of riboflavin. The riboflavin solution is characterized by a pH of 7.40, con-
ductivity of 135 /iS/cm and an osmolarity of 308 mosmol/1. For dose-response experiments, 150
nM and 75 /*M concentrations of riboflavin were also used.
Experimental Groups. In the CVF model, one group of animals (n = 9, 300-350 g body
weight) received 2 ^moles riboflavin/kg (between 2 and 2.3 ml of the 300 pM riboflavin solution)
intravenously 10 minutes prior to CVF. The positive control group (n = 9) received intravenously
glucose-saline solution with no riboflavin prior to CVF. Other groups of rats were injected intra-
peritoneally 10 minutes prior to CVF with 6 fmoles riboflavin/kg (6-7 ml of a 300 mM riboflavin
solution; n = 9), 3 /imoles riboflavin/kg (6-7 ml of a 150 ftM riboflavin solution; n = 6), or 1.5
ftmoles riboflavin/kg (6-7 ml of a 75 ^M riboflavin solution; n = 6). Positive control animals (n =
9) received the glucose-saline solution with no riboflavin intraperitoneally prior to CVF. Negative
controls (n = 6) were anesthetized and received glucose-saline but no riboflavin or CVF.
Animals subjected to immune complex-mediated alveolitis received intraperitoneally 1.5
/imoles riboflavin/kg body weight (between 1.5 and 1.75 ml of the 300 /tM riboflavin solution)
10 minutes prior to injury, followed by subsequent injections of 1.5 /tmoles riboflavin/kg at 30, 60,
and 120 minutes (n = 9). Positive control animals were treated identically but without riboflavin
(n = 9). A negative control group was anesthetized and received glucose-saline solution only (n
= 6).
In the ischemia-reperfusion model, animals (n = 8) were injected intraperitoneally with 1.5
/imoles riboflavin/kg (between 1.5 and 1.75 ml of the 300 /iM riboflavin solution) 10 minutes prior
to reperfusion, followed by subsequent injections of 1.5 /tmoles riboflavin/kg at 30, 60, and 120 min
of reperfusion. Positive control animals (n = 6) received only the glucose-saline solution in the same
protocol. To assess the effect of ischemia itself, one group (n = 6) of animals was sacrificed at the
end of the ischemia phase. A negative control group was anesthetized and received glucose-saline
solution only (n = 6).
Tissue Myeloperoxidase Content. Neutrophil sequestration in lungs and muscle was assessed
by measuring the myeloperoxidase (MPO) content. As has been demonstrated, MPO activity directly
correlates with the number of neutrophils in the tissues (16). The total lung and the dissected muscle
were first homogenized (Tissumizer, Tekmar Comp., Cincinnati, Ohio) in 50 mM potassium phos-
phate buffer (pH 6.0) with 5 mM EDTA and 0.5% hexadecylmethyl ammonium bromide (HTAB).
The suspension was then sonicated (W 380, Sonicator, Heat Systems-Ultrasonics Inc., Farmingdale,
New York) and centrifuged at 3000 x g for 30 min at 4°C. The supernatant fraction (50 /il aliquot)
was added to 1.45 ml of 100 mM potassium phosphate buffer containing 3% hydrogen peroxide
and 1% o-dianisidine hydrochloride (ODH). Myeloperoxidase activity was assayed by recording the
change in absorbance at 460 nm over 3 min.
Lipid Peroxidation. Lung and plasma samples from rats subjected to CVF-induced lung injury
were evaluated for lipid peroxidation by measuring conjugated dienes as previously described (17).
Briefly, plasma samples were dissolved in a chloroform/methanol mixture (2:1, v/v) and then cen-
trifuged at 1500 x g. The bottom layer was dried under nitrogen gas and its residue then dissolved
in heptane for reading the absorbance of conjugated dienes at 233 nm. Tissue samples were first
homogenized and then processed as described for plasma.
Statistical Analysis. All data were first subjected to one- and two-way analysis of normal
variance (ANOVA). Individual group mean values were then compared using Student's t test. A
value of P < 0.05 was considered to be significant. All data in the graphs are presented as mean ±
standard error of the mean (SEM). For calculation of % protection, mean negative control (saline,
sham) values or the "ischemia only" values were first subtracted from all positive and treatment
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group values. The difference between the positive control and treatment values was then expressed
as percentage of the positive control.
RESULTS
CVF Lung Injury Model. Intravenous injection of CVF (20 units/kg BW)
resulted in a six-fold increase in lung vascular permeability within 30 minutes.
Intravenous injection of riboflavin (2 /imoles/kg body weight) in this model
resulted in a 39% reduction (Figure 1) of lung vascular permeability (P < 0.02).
In order to examine the effect of increased concentrations of riboflavin, larger
volumes of the saturated solution were injected. Here, the riboflavin was admin-
istered intraperitoneally in order to avoid hemodynamic changes due to increased
blood volume. Administration of 6 /imoles riboflavin/kg produced a protection
of 56% in vascular permeability (P < 0.01, Figure 1) and reduced 51Cr-RBC
extravasation by 76% (P < 0.01, Table 1). When 3 /tmoles riboflavin/kg were
Fig. 1. Dose-dependent protective effect of riboflavin on cobra venom fetor (CVF)-induced acute
lung injury in the rat. Intravenous injection of 2 ^moles riboflavin/kg body weight as well as intra-
peritoneal injection of 6 ftmoles riboflavin/kg (but not 3 or 1.5 fimoles/kg of riboflavin) provided
significant protection against lung microvascular leakage of 125I-labeled bovine serum albumin as
measured at 30 minutes after CVF injection.






























aLung injury (alveolar hemorrhage) was assessed by extravasation of 51Cr-labeled rat erythrocytes.
bRiboftavin (6 /imoles/kg BW), given intraperitoneally.
cP < 0.05.
injected, the protective effect in vascular permeability dropped to 17% (P = 0.05)
(Figure 1). Administration of 1.5 /*moles/kg (Figure 1) gave only 6% protection
(not significant).
Lung and plasma samples obtained from CVF-treated rats showed a two-
fold incresae in conjugated dienes compared to negative controls (Figure 2).
The intraperitoneal administration of 6 /*moles riboflavin/kg body weight prior
to CVF injection reduced conjugated dienes in lung tissue by 45% (P < 0.01)
and in plasma by 75% (P < 0.01).
Measurements of myeloperoxidase (MPO) content in the lungs of experi-
mental animals revealed that CVF alone caused a two-fold increase in lung neu-
trophil accumulation (Table 2). When administered at the protective dose shown
in Table 1, riboflavin did not cause a significant reduction in lung myeloperox-
idase content.
IgG Immune Complex Alveolitis Model. The simultaneous administration
of intravenous BSA (10 mg) and intratracheal anti-BSA (2.5 mg) resulted in a
seven-fold increase in lung vascular permeability (Figure 3). When rats were
treated with riboflavin at the same concentration that was effective in the CVF
model (6 /^moles/kg, given intraperitoneally), vascular permeability was reduced
by 44% (P < 0.01; Figure 3) and hemorrhage was reduced by 51% (P <
0.01; Table 1). Neutrophil accumulation increased four-fold in this model. This
increase was not influenced by the administration of riboflavin (Table 2).
Ischemia-Reperfusion Model. Four hours of bilateral hind limb ischemia
followed by 4 h of reperfusion caused a seven-fold increase in muscle vascular
permeability (Figure 4A) and a four-fold increase in lung vascular permeabil-
ity (Figure 4B), compared to 4 h of ischemia only. Since the major damage
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Fig. 2. Effect of riboflavin on lung and plasma levels of conjugated dienes in rats injected with cobra
venom factor (CVF). Riboflavin was injected intraperitoneally at a dose of 6 ^moles/kg body weight,
causing reductions in lung and plasma levels of conjugated dienes by 45% and 75%, respectively,
as measured at 30 min after CVF injection.
occurred during the reperfusion phase, intraperitoneal treatment with riboflavin
was started 10 minutes prior to the reperfusion. In this type of injury, treatment
with the highest dose of riboflavin tested in the CVF model (6 /tmoles/kg body
weight) reduced muscle vascular permeability by 22% (P < 0.05) (Figure 4A)
and lung vascular permeability by 58% (P < 0.01) (Figure 4B). Muscle hemor-
Table 2. Effect of Riboflavin on Lung Myeloperoxidase Content in Rats Submitted to

























0.44 ± 0.029 (N.S.)
aRiboflavin (6 ^moles/kg BW), given intraperitoneally. N.S. = not significant.
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rhage was reduced by 30% (P < 0.05; data not shown) and lung hemorrhage by
70% (P < 0.01, Table 1). During reperfusion of the limbs, neutrophil sequestra-
tion increased more than four-fold in the lung as well as in the muscle and, again,
as seen in the other inflammatory models, lung content of myeloperoxidase was
not altered by riboflavin treatment (Table 2).
DISCUSSION
Riboflavin in its reduced form (dihydroriboflavin) has been shown to reduce
ferric hemeproteins (18) and the products resulting from the reactions of heme-
proteins with peroxides (11). Since dihydroriboflavin is spontaneously oxidized
to riboflavin the oxidized form was administered to rats in the present experi-
ments. Our hypothesis is that riboflavin penetrates into cells (e.g., the endothe-
lial cell) and is converted to dihydroriboflavin by the enzyme, flavin reductase.
By such a mechanism, hydroxyl radical and Fe(IV)O- and Fe(V)-hemeproteins
will be scavenged within the cell, (10, 11) but oxygen radicals that are already
released by a cell would not be affected by riboflavin.
To examine if riboflavin may protect from oxygen radical-mediated mi-
Fig. 3. Protective effect of riboflavin (6 /*moles/kg, intraperitoneally) on lung vascular leakage
(125I-BSA) in immune-complex alveolitis in the rat. Vascular permeability was measured at 4 h
after antigen and antibody injection.
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Fig. 4. Protective effects of riboflavin (6 ^moles/kg, intraperitoneally) on muscle (A) and lung
(B) vascular leakage (125I-BSA) after bilateral hind limb ischemia-reperfusion (I/R). Permeability
measurements were performed after 4 h of ischemia (I) and 4 h of reperfusion.
crovascular injury in vivo, well-characterized rat models of oxidant-mediated
lung injury were employed. In the CVF model, systemic complement activa-
tion due to cobra venom factor initiates lung injury, which is characterized by
neutrophil accumulation along the vascular endothelium leading to subsequent
Vitamin B2 Protects Against Oxidant Lung Injury
endothelial cell and basement membrane damage resulting in increased lung vas-
cular leakage and alveolar hemorrhage within 30 min after CVF injection (3).
Furthermore, the lung microvascular injury is accompanied by the appearance in
plasma and lung tissues of lipid peroxidation products (17). Both lung injury and
lipid peroxide generation are significantly attenuated by pretreatment of experi-
mental animals with catalase, hydroxyl radical scavengers or iron chelators, (3,
17) suggesting that complement-mediated activation of blood neutrophils and
their generation of an iron-catalyzed conversion product of hydrogen peroxide,
most likely the hydroxyl radical, are directly responsible for the observed lung
injury. The IgG immune complex-induced lung injury results in extensive neu-
trophil accumulation, much of it being extravascular. Similar to the CVF model,
the accompanying microvascular damage can largely be attenuated by pretreat-
ment of experimental animals with catalase, hydroxyl radical scavengers, or iron
chelators (4). Ischemia of hind limbs of rats followed by reperfusion is charac-
terized by increased vascular leakage locally in the muscle and distantly in lungs
(5). As in the previous two models, the microvascular injury can be significantly
reduced by treatments of rats with antioxidants (5).
In all three of our in vivo models we have shown that vascular leakage and
hemorrhage are significantly attenuated by riboflavin. The decrease in lipid per-
oxidation in the CVF model suggests that the mechanism of riboflavin-mediated
protection is releated to oxygen radical scavenging. Previous studies have shown
that scavenging of oxygen radicals not ony protects from vascular injury but
also can decrease neutrophil accumulation (19). Oxidants released by endothelial
cells (20) may be involved in the generation of chemotactic factors (21) and have
recently been shown to up-regulate neutrophil adhesion molecules (22,23). Since
riboflavin had no effect on neutrophil sequestration (Table 2), it appears that
riboflavin may not scavenge extracellular oxygen radicals released from endo-
thelial cells. Most likely, intracellular reactive oxygen species that directly dam-
age endothelial cells are scavenged by the reduced form of riboflavin, dihydro-
riboflavin. Furthermore, riboflavin has no effect on the generation of superoxide
or hydrogen peroxide by activated rat neutrophils in vitro (A. Seekamp, unpub-
lished observation), suggesting that the protective effect of riboflavin is not due
to inhibition of oxidant production by activated neutrophils.
In summary, our results demonstrate that riboflavin, in a dose-dependent
manner, protects the lungs from oxygen radical-mediated injury without affectig
neutrophil accumulation in vivo. We propose that in order to scavenge oxygen
radicals and protect vascular endothelial cells from injury, riboflavin is converted
into dihydroriboflavin by flavin reductase, an intracellular enzyme.
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